{
  "source": "PA-Med-Nec-Dry-Eye-Disease.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2107-14\nProgram Prior Authorization – Medical Necessity\nMedication Cequa™ (cyclosporine 0.09% ophthalmic solution)*, Restasis®\nMultiDose™ (cyclosporine 0.05% ophthalmic emulsion)*, Tyrvaya™\n(varenicline nasal spray), Vevye™ (cyclosporine 0.1%)*\nP&T Approval Date 9/2016, 9/2017, 9/2018, 3/2019, 4/2020, 4/2021, 12/2021, 7/2022,\n7/2023, 9/2023, 3/2024, 7/2024\nEffective Date 8/18/2024\n1. Background:\nCequa (cyclosporine 0.09% ophthalmic solution)* and Restasis MultiDose (cyclosporine 0.05%\nophthalmic emulsion)* are indicated to increase tear production in patients whose tear\nproduction is presumed to be suppressed due to ocular inflammation associated with\nkeratoconjunctivitis sicca.\nTyrvaya (varenicline nasal spray), Vevye (cyclosporine 0.1%)* and Xiidra (lifitegrast 5%\nophthalmic solution) are indicated for the treatment of the signs and symptoms of dry eye\ndisease.\n2. Coverage Criteria a:\nA. Cequa*, Restasis MultiDose* or Vevye*\n1. Initial Authorization\na. Cequa*, Restasis MultiDose* or Vevye* will be approved based on all of the\nfollowing:\n(1) Tear deficiency associated with ocular inflammation due to one of the\nfollowing:\n(a) Moderate to severe keratoconjunctivitis sicca\n-OR-\n(b) Moderate to severe dry eye disease\n-AND-\n(2) Not prescribed to manage dry eyes peri-operative elective eye surgery (e.g.:\nLASIK)\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n1\n(3) History of failure to at least one OTC artificial tear product (e.g., Systane®\nUltra, Akwa® Tears, Refresh Optive®, Soothe® XP)\n-AND-\n(4) History of failure, contraindication or intolerance to both of the following:\n(a) Restasis single dose vials\n(b) Xiidra\n-AND-\n(5) Medication will not be used in combination with another prescription product\nfor dry eye disease or keratoconjunctivitis sicca (e.g., Miebo, Restasis single\ndose-vials, Tyrvaya, Xiidra)\n-AND-\n(6) Prescribed by or in consultation with one of the following:\n(a) Ophthalmologist\n(b",
    "or dry eye disease or keratoconjunctivitis sicca (e.g., Miebo, Restasis single\ndose-vials, Tyrvaya, Xiidra)\n-AND-\n(6) Prescribed by or in consultation with one of the following:\n(a) Ophthalmologist\n(b) Optometrist\n(c) Rheumatologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cequa*, Restasis MultiDose*, or Vevye* will be approved based on the following\ncriterion:\n(1) Patient has demonstrated clinically significant improvement with therapy\n-AND-\n(2) Medication will not be used in combination with another prescription product for\ndry eye disease or keratoconjunctivitis sicca (e.g., Miebo, Restasis single dose-\nvials, Tyrvaya, Xiidra)\nAuthorization will be issued for 12 months.\nB. Tyrvava\n1. Initial Authorization\na. Tyrvaya will be approved based on all of the following:\n(1) Tear deficiency associated with ocular inflammation due to one of the\nfollowing:\n(a) Moderate to severe keratoconjunctivitis sicca\n© 2024 UnitedHealthcare Services, Inc.\n2\n-OR-\n(b) Moderate to severe dry eye disease\n-AND-\n(2) Not prescribed to manage dry eyes peri-operative elective eye surgery (e.g.:\nLASIK)\n-AND-\n(3) History of failure to at least one OTC artificial tear product (e.g., Systane®\nUltra, Akwa® Tears, Refresh Optive®, Soothe® XP)\n-AND-\n(4) History of failure, contraindication or intolerance to both of the following:\n(a) Restasis single dose vials\n(b) Xiidra\n-AND-\n(5) Medication will not be used in combination with another prescription product\nfor dry eye disease or keratoconjunctivitis sicca (e.g., Cequa, Miebo, Restasis,\nVevye, Xiidra)\n-AND-\n(6) Prescribed by or in consultation with one of the following:\n(a) Ophthalmologist\n(b) Optometrist\n(c) Rheumatologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tyrvaya will be approved based on the following criterion:\n(1) Patient has demonstrated clinically significant improvement with therapy\n-AND-\n(2) Medication will not be used in combination with another prescription product\nfor dry eye disease",
    "owing criterion:\n(1) Patient has demonstrated clinically significant improvement with therapy\n-AND-\n(2) Medication will not be used in combination with another prescription product\nfor dry eye disease or keratoconjunctivitis sicca (e.g., Cequa, Miebo, Restasis,\nVevye Xiidra)\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n3\na. State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n*Cequa, Restasis MultiDose and Vevye* are typically excluded from coverage.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place\n• Prior Authorization – Notification may be in place\n4. References:\n1. Cequa [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc; December 2022.\n2. Restasis [package insert]. Irvine, CA: Allergan, Inc.; July 2017.\n3. Restasis MultiDose [package insert]. Irvine, CA: Allergan, Inc.; October 2016.\n4. Tyrvaya [package insert]. Princeton NJ: Oyster Point Pharma, Inc; February 2024\n5. Vevye [package insert]. Nashville, TN: Harrow Eye, LLC; November 2023.\n6. Xiidra [package insert]. Bridgewater, NJ: Bausch & Lomb Americas Inc;December 2023.\n7. American Academy of Ophthalmology. Dry Eye Syndrome Preferred Practice Pattern 2023.\nProgram Prior Authorization – Medical Necessity – Dry Eye Disease\nChange Control\n9/2016 New program.\n11/2016 Administrative change. Added California coverage information.\n9/2017 Annual review. Administrative updates. Added Restasis MultiDose.\nUpdated references.\n9/2018 Annual review. Administrative updates and updated references.\n12/2018 Administrative change t",
    "mation.\n9/2017 Annual review. Administrative updates. Added Restasis MultiDose.\nUpdated references.\n9/2018 Annual review. Administrative updates and updated references.\n12/2018 Administrative change to add statement regarding use of automated\nprocesses.\n3/2019 Added Cequa and updated references.\n4/2020 Annual review. Added a step through Restasis single use vials for\nCequa and Restasis MultiDose. Updated references.\n4/2021 Annual review. Updated references.\n12/2021 Added Tyrvava.\n7/2022 Removed Restasis single dose vials and Xiidra from the criteria.\n7/2023 Annual review. Added step through Xiidra for Cequa & Restasis\nMultidose. Updated references.\n9/2023 Added Miebo and Vevye.\n3/2024 Updated the initial authorization to 12 months. Updated references.\n7/2024 Removed Miebo from Medical Necessity criteria. Added language on\nconcomitant therapy. Removed referenced to compound Notification.\n© 2024 UnitedHealthcare Services, Inc.\n4"
  ]
}